Camsirubicin is a novel proprietary analog of the widely used cancer drug doxorubicin. Doxorubicin is used to treat adult and pediatric solid and hematologic (blood) cancers including breast, gastric, ovarian and bladder cancer, soft tissue sarcomas, leukemias and lymphomas. Numerous clinical studies have demonstrated the anticancer benefit of higher doses of doxorubicin. The optimal clinical efficacy of doxorubicin, however, is limited by the risk of patients developing irreversible, potentially life-threatening cardiotoxicity at higher doses. Camsirubicin has been engineered specifically to retain the anticancer activity of doxorubicin while minimizing the toxic effects on the heart. Preclinical and early clinical studies support the hypothesis that camsirubicin will be less cardiotoxic while retaining anti-cancer activity. Monopar believes the results of these studies, along with the potential to combine a less or non-cardiotoxic analog of doxorubicin with other anticancer agents, emphasizes a large market opportunity for camsirubicin in a broad spectrum of cancer types.
The antitumor effects of camsirubicin are mediated through mechanisms common to all anthracyclines including doxorubicin. These mechanisms include the stabilization of the topoisomerase II complex after a DNA strand break and DNA intercalation leading to apoptosis (cell death). Inhibiting the topoisomerase IIα isoform achieves the anticancer effect, while inhibiting the topoisomerase IIβ isoform, which is expressed in cardiomyocytes but not in cancer cells, mediates, at least in part, the cardiotoxicity associated with all anthracycline drugs currently used in the clinic. In contrast to doxorubicin, camsirubicin exhibits some selectivity for inhibiting the topoisomerase IIα isoform over the topoisomerase IIβ isoform. This selectivity may explain the minimal cardiotoxicity that camsirubicin has demonstrated in clinical studies to date.
Learn more about the clinical studies that support the safety and efficacy of Camsirubicin.